A daily pill that slashes LDL could change how we fight heart disease

FDA-approved enlicitide is an oral pill that lowers LDL cholesterol by about 60%, offering a needle-free alternative to injections and statins for those who can’t tolerate them; the drug’s development builds on PCSK9 genetics, and while LDL reductions look promising, hard outcomes like deaths will take years to prove, and cost and access—alongside the potential of gene editing and other therapies—will shape how broadly it helps curb heart disease.